Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Public ClinicalTrials.gov record NCT01254578. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies
Study identification
- NCT ID
- NCT01254578
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Promyelocytic Leukemia With PML-RARA
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Alkylating Agent-Related Acute Myeloid Leukemia
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-Cell Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Hepatosplenic T-Cell Lymphoma
- Intraocular Lymphoma
- Lymphomatous Involvement of Non-Cutaneous Extranodal Site
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Nodal Marginal Zone Lymphoma
- Post-Transplant Lymphoproliferative Disorder
- Primary Cutaneous B-Cell Non-Hodgkin Lymphoma
- Prolymphocytic Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Immunoblastic Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides and Sezary Syndrome
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Richter Syndrome
- Small Intestinal Lymphoma
- Splenic Marginal Zone Lymphoma
- T-Cell Large Granular Lymphocyte Leukemia
- Testicular Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- Laboratory Biomarker Analysis Other
- Lenalidomide Drug
- Pharmacological Study Other
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2010
- Primary completion
- Nov 8, 2012
- Completion
- Nov 8, 2012
- Last update posted
- Sep 24, 2017
2010 – 2012
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01254578, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2017 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01254578 live on ClinicalTrials.gov.